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 BRCA2 و BRCA1 توقع امكانية حدوث األمراض للمتغريات اجلينية ل
احملددة يف الفحص اجليين السريري
كلري بروك�ض، �ستيال الي، الني دوروثي، دونالد لوف
abstract: Objectives: Missense variants are very commonly detected when screening for mutations in the 
BRCA1 and BRCA2 genes. Pathogenic mutations in the BRCA1 and BRCA2 genes lead to an increased risk of 
developing breast, ovarian, prostate and/or pancreatic cancer. This study aimed to assess the predictive capability 
of in silico programmes and mutation databases in assisting diagnostic laboratories to determine the pathogenicity 
of sequence-detectable mutations. Methods: Between July 2011 and April 2013, an analysis was undertaken of 
13 missense BRCA gene variants that had been detected in patients referred to the Genetic Health Services New 
Zealand (Northern Hub) for BRCA gene analysis. The analysis involved the use of 13 in silico protein prediction 
programmes, two in silico transcript analysis programmes and the examination of three BRCA gene databases. 
Results: In most of the variants, the analysis showed different in silico interpretations. This illustrates the 
interpretation challenges faced by diagnostic laboratories. Conclusion: Unfortunately, when using online mutation 
databases and carrying out in silico analyses, there is significant discordance in the classification of some missense 
variants in the BRCA genes. This discordance leads to complexities in interpreting and reporting these variants in a 
clinical context. The authors have developed a simple procedure for analysing variants; however, those of unknown 
significance largely remain unknown. As a consequence, the clinical value of some reports may be negligible.
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BRCA2. والطفرات امل�سببة  BRCA1 و  الهدف: تكت�سف املتغريات املغلوطة ب�سورة �سائعة عند فح�ض الطفرات يف جينات  امللخ�ص: 
لالأمرا�ض يف جيني BRCA1 و BRCA2 توؤدي ايل زيادة خطورة حدوث �رشطانات الثدي واملباي�ض والربو�ستاتا والبنكريا�ض. وهدفت 
هذه الدرا�سة ايل تقييم القدرة التنبوؤية لقواعد بيانات وبرامج "انسيليكو" مل�ساعدة املعامل الت�سخي�سية يف حتيد قدرة الطفرات الت�سل�سلية علي 
الت�سبب يف االأمرا�ض. الطريقة: مت حتليل 13 متغري مغلوط يف جينات ال BRCA يف الفرتة مابني يوليو 2011 ايل ابريل 2013 يف عينات 
13 برنامج  BRCA. وا�ستخدم يف التحليل  )Northern Hub( لتحليل جينات ال  املر�سي املحولة ايل اخلدمات ال�سحية النيوزيالندية 
"انسيليكو" التنبوؤى للربوتني، واثنني برنامج "انسيليكو" للتحليل الن�سي وفح�ض ثالثة قواعد بيانات جلني ال BRCA. النتائج: اأظهرت نتائج 
الت�سخي�سية يف تف�سري هذه  التي تواجه املعامل  التحديات  "انسيليكو" ملعظم املتغريات. وهذا يو�سح  التحليل اختالفا ملحوظا يف تف�سري 
النتائج. اخلال�صة: لالأ�سف فانه يحدث الكثري من االأختالف عند ت�سنيف املتغريات املغلوطة يف جني ال BRCA باأ�ستخدام قواعد بيانات 
ال�سبكة العنكبوتية لتنفيذ حتليل "انسيليكو". وقد اأدي هذا االأختالف ايل حدوث تعقيدات كبرية يف تف�سري هذه املتغريات يف ال�سياق ال�رشيري. 
وقد طور الباحثون طريقة ب�سيطة لتحليل املتغريات ولكن بالرغم من ذلك فانه اليزال هناك الكثري منها غري معلوم الداللة. وبالتايل فاأن 
القيمة ال�رشيرية لبع�ض هذه التقارير ميكن اإهمالها.
مفتاح الكلمات: اجلينات، BRCA1؛ واجلني، BRCA2؛ متالزمة HBOC؛ "انسيليكو".
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Advances in Knowledge 
- The analysis of sequence-detectable variants in the BRCA1 and BRCA2 (BRCA1/2) genes is critical in establishing if these variants are 
disease-causing.
- The analysis presented here shows the challenges posed by in silico programmes. 
- Diagnostic laboratories may therefore have to rely on familial segregation studies or the development of better in silico programmes 
possibly based on advanced neural network modelling requiring phenotypic as well as genotypic data. 
Appication to Patient Care
- The analysis in this study shows the advantages and disadvantages of database searching and in silico analyses in predicting the 
pathogenicity of gene variants.
- In the case of BRCA1/2 gene variants, evolving analytical tools offer an improved outcome for guiding counselling of patients at risk of 
hereditary breast and ovarian cancer.
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Pathogenic mutations in the BRCA1 and BRCA2 (BRCA1/2) genes predispose patients to an increased risk of developing 
breast, ovarian, prostate and/or pancreatic cancer; 
these genes are two of the genes most commonly 
tested for cancer predisposition. In the USA, a known 
pathogenic mutation is detected in approximately 
10–15% of patients who undergo sequencing of the 
entire coding regions of the BRCA genes.1 However, a 
variant of uncertain significance (VUS) is detected in 
more than 5% of patients, with higher frequencies seen 
in less commonly tested ethnic groups.2
Patients with known pathogenic BRCA gene 
mutations are offered preventative strategies including 
enhanced surveillance, chemoprevention and 
irreversible surgical interventions. A study of patients 
in the USA, surveyed two years after being given 
either an uninformative (UN) BRCA gene-negative 
or VUS result by trained genetic counsellors, found 
that a VUS result did not result in excessive surgeries, 
exaggerated distress or increased risk perception 
compared to patients with a UN result.3 The risk-
reducing mastectomy rate was 7% in both groups and 
the oophorectomy rate was 5% for VUS patients and 
3% for UN patients.3
A pathogenic mutation refers to a genetic variant 
that has been shown to cause or contribute to disease. 
A benign variant does not significantly impact on the 
function of the protein or increase disease risk, and 
it includes polymorphisms which are seen in over 
1% of the general population. A VUS is a variant 
where the effect on protein function and disease risk 
is unknown.4 In the case of the BRCA genes, VUS 
are largely missense substitutions where a single 
nucleotide change results in an altered amino acid. 
The terms, VUS and unclassified variant (UV) are 
often used interchangeably in the literature; however, 
they have slightly different interpretations. The term 
UV is suggestive of an unstudied variant, whereas a 
VUS may or may not have been studied but still has 
unknown clinical relevance.5
Providing a clear interpretation of a VUS is 
a complex challenge for a diagnostic laboratory. 
Common methods used to predict pathogenicity 
can include literature and database searches, in silico 
analyses, segregation analyses and functional studies. 
The requesting clinician may be faced with the 
difficult task of deciphering the ambiguity of the VUS 
and communicating the result to the patient along 
with clinical recommendations. Furthermore, it is 
imperative that the classifications of VUS are regularly 
checked and any changes to their classifications are 
relayed to the patients and their family.
The majority of missense mutations in the BRCA 
genes are classified as VUS. The exceptions include 
missense mutations that lie within the highly conserved 
BRCA1 RING and the BRCA1 carboxyl-terminal 
domains.6 Known pathogenic missense mutations in 
the BRCA2 gene are less common but may occur in 
the DNA-binding domain.7
The difficulty in the interpretation of missense 
variants in the BRCA genes arises due to the 
discordance in the classification of variants in the 
breast cancer databases and the variety of predictions 
based on in silico analyses. Recently, Lindor et al. used 
a quantitative posterior probability model to reclassify 
VUS in the BRCA1/2 genes into five classes as defined 
by the International Agency for Research on Cancer 
(IARC) Working Group on Unclassified Genetic 
Variants.8 These classes range from class 1 (not 
pathogenic) through to class 5 (definitely pathogenic). 
This reclassification attempts to combine a range of 
information regarding each VUS in the literature and 
convert this into a useful posterior probability.
This study analysed nine BRCA1 and four BRCA2 
gene missense variants identified in the Diagnostic 
Genetics LabPLUS, Auckland City Hospital, Auckland, 
New Zealand, where the interpretation was hampered 
by the diversity of classifications in international 
databases and online in silico predictions.
Methods
This study was carried out between July 2011 and 
April 2013 and included 20 patients referred to 
Genetic Health Services New Zealand (Northern 
Hub) for BRCA1/2 gene mutation screening. DNA 
was extracted from peripheral blood samples in 
ethylenediaminetetraacetic acid (EDTA) using the 
Gentra Puregene DNA Extraction kit (Qiagen GmbH, 
Hilden, Germany). 
Genomic DNA from 20 patients were subjected 
to BRCA1/2 gene sequencing as described elsewhere;9 
any identified variants were subsequently confirmed by 
exon-targeted polymerase chain reaction amplification 
and bi-directional Sanger-based sequencing.10 Sequence 
traces were analysed using KB Basecaller Version 1.4 
(Applied Biosystems Inc., Foster City, California, USA), 
on Variant Reporter™ Software Version 1.0 (Applied 
Biosystems Inc.), with a minimum trace score of 35, which 
corresponds to an average false base-call frequency of 
0.031%. The analysis of sequence data and the subsequent 
investigation of databases and bioinformatic programmes 
used the relevant Reference Sequence (RefSeq) transcript, 
RefSeq protein and Uniprot accession numbers for the 
BRCA1 (NM_007294.3; NP_009225.1; P38398) and 
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BRCA2 (NM_000059.3; NP_000050.2; P51587) genes.
All variants were checked for splicing effects 
using two in silico splice prediction programmes: the 
Splice Site Prediction by Neural Network online tool 
of the Berkeley Drosophilia Genome Project and the 
Alternative Splice Site Predictor (ASSP) tool.11–14
All of the patients included in the study gave informed 
consent. The New Zealand Multi-Region Ethics 
Committee has ruled that cases of patient management 
do not require formal ethical approval from a committee.
Results
The missense BRCA gene variants identified are 
shown in Table 1. These variants were checked for 
pathogenicity in six databases (three of which were 
specific to the BRCA genes)[Figure 1 and Table 2].8,15‒19
The missense variants were also scored for predic-
ted pathogenicity using 13 online in silico protein 
analysis programmes [Figure 2 and Table 3].20‒43 When 
all variants were checked for splicing effects using the two 
aforementioned in silico splice prediction programmes, 
both of the programmes predicted that each variant 
would have no effect on splicing (data not shown).
Apart from four of the variants, the results of the in 
silico protein analysis programmes varied depending 
on which programme was used. The frequency with 
which variants were predicted to be pathogenic varied 
significantly between programmes [Table 4].22‒43
A total of 13 missense BRCA gene mutations were 
identified and only one was identified as probably 
pathogenic (BRCA1: c.140G>A) based on the 
combined results achieved from databases and in silico 
programmes. However, this variant was predicted to 
be benign using the Polymorphism Phenotyping, 
Version 2 (PolyPhen-2), HumVar database and the 
Protein Variation Effect Analyzer (PROVEAN).20,37 
In addition, a further three variants appeared to be 
probably benign (BRCA1: c.2612C>T, c.3548A>G and 
BRCA2: c.2971A>G). However, the remaining nine 
variants could not be interpreted even though minor 
allele frequencies on the Database of Single Nucleotide 
Polymorphisms (dbSNP) ranged from 0.01 to 0.327.19
Table 1: Missense BRCA gene mutations identified in 






















Figure 1: Diagrammatic representation of the pathogenicity calls of 13 BRCA gene missense variants in six databases, 
including the (1) Human Gene Mutation Database Professional 2013;15 (2) Breast Cancer Information Core;16 (3) 
Universal Mutation Database;17 (4) Leiden Open Variation Database;18 (5) International Agency for Research on Cancer,8 
and (6) Database of Single Nucleotide Polymorphisms.19
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IARC class dbSNP dbSNP 
MAF
BRCA1
c.140G>A DM Not listed Not listed 5 – Causal Not listed Not listed -
c.1067A>G DP Unknown Mixed 1 – Neutral 1 - not path rs1799950 C = 0.028
c.2077G>A DP No Mixed 1 – Neutral 1 - not path rs4986850 T = 0.039
c.2315T>C DM Unknown Neutral 1 – Neutral 1 - not path rs80357467 -
c.2612C>T DFP1 No Mixed 1 – Neutral 1 - not path rs799917 A = 0.483
c.3113A>G DP2 No Mixed 1 – Neutral 1 - not path rs16941 C = 0.303
c.3119G>A DM? Unknown Neutral 1 – Neutral 1 - not path rs4986852 T = 0.012
c.3548A>G DP1 No Mixed 1 – Neutral 1 - not path rs16942 C = 0.324
c.4837A>G DM? No Mixed 1 – Neutral 1 - not path rs1799966 C = 0.327
BRCA2
c.865A>C DP1 No Mixed 1 - Neutral Not listed rs766173 C = 0.058
c.1114A>C DFP Listed as 
C>A
Neutral Listed as C>A Listed as 
C>A
rs144848 C = 0.240
c.2971A>G DM? No Neutral Polymorphism Not listed rs1799944 G = 0.062
c.8149G>T DM? No Neutral 1 - Neutral 1 - not path rs28897747 T = 0.001
HGMD = Human Gene Mutation Database Professional 2013;15 BIC = Breast Cancer Information Core database;16 LOVD = Leiden Open 
Variation Database;18 UMD = Universal Mutation Database;17 IARC = International Agency for Research on Cancer;8 dbSNP = Database of 
Single Nucleotide Polymorphisms;19 MAF = minor allele frequency; DM = disease-causing mutation; DP = disease-associated polymorphism; path 
= pathogenic; DFP = disease-associated polymorphism with additional supporting functional evidence; 1 = associated with a decreased risk; 2 = 
comments included “polymorphism”; DM? = potential disease-causing mutation. 
 
Figure 2: Diagrammatic representation of the pathogenicity calls of 13 BRCA gene missense variants using 13 online 
in silico analysis programmes (all used in default online mode). These prediction programmes included: both the (1) 
HumDiv and (2) HumVar predictions of Polymorphism Phenotyping, Version 2;20,21 (3) Mutation Assessor, release 2;22,23 
(4) I-Mutant, Version 3.0, for the prediction of disease-associated single point mutations from protein sequence;24,25 (5) 
MutPred, Version 1.2;26,27 (6) SNPs&GO;28,29 (7) Protein Analysis Through Evolutionary Relationships Evolutionary Analysis 
of Coding SNPs, Version 6.1;30,31 (8) Align-Grantham Variation Grantham Deviation used with the supplied BRCA1 and 
BRCA2 alignments;32,33 (9) SNAP;34,35 (10) Predictor of Human Deleterious Single Nucleotide Polymorphisms;36 (11) 
Protein Variation Effect Analyzer, Version 1.1.3, and Sorting Intolerant from Tolerant;37–39 (12) Sorting Intolerant from 
Tolerant BLink,40,41 and (13) Mutation Taster.42,43
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Discussion
The results presented here illustrate a major problem 
in interpreting missense BRCA1/2 gene variants. 
The classifications from various databases and the 
predictions from a variety of online in silico analysis 
programmes can vary widely. This highlights the risk 
of relying on information obtained from just one 
database or from using only a few in silico programmes 
when reporting missense variants, as the outcome can 
affect clinical surveillance and prevention decisions.
Of the 13 missense BRCA gene mutations 
identified, only one was shown to be probably 
pathogenic, although the same variant was predicted 
to be benign by the PolyPhen-2 HumVar database 
and PROVEAN.20,37 Lindor et al. classified nine 
of the variants in their study as IARC class 1 (not 
pathogenic).8 Their reclassification uses a model based 
on prior probabilities derived from evolutionary 
predictions combined with a likelihood component 
from segregation information, co-occurrence in ‘trans’, 
personal and family history and a histopathology 
profile to give a posterior probability of causality. The 
outcome of this analysis is based on combining a wide 
range of information, which is clearly different from the 
predictions made from individual databases and single in 
silico programmes, and again highlights the importance 
of an over-reliance on one source of information to 
determine the disease causality of a variant.
The Clinical Molecular Genetics Society (CMGS) 
in the UK states in their 2007 guidelines for interpre-
ting and reporting UVs that it is unacceptable to rely 
solely on in silico predictions to assign pathogenicity 
to a previously unclassified variant.44 Furthermore, 
the Association for Clinical Genetic Science states 
in their 2013 practice guidelines for the reporting of 
sequence variants in clinical molecular genetics that 
“the classification generated from the prediction tools 
must not be considered definitive”.45 The American 
College of Medical Genetics (ACMG) guidelines state 
that all variants of unknown clinical significance must 
be included in a laboratory’s report and be followed by 
an interpretation of their likely clinical significance.46 
ACMG recommend categorising uncertain sequence 
variants as either “previously unreported and of 
the type which may or may not be causative of the 
disorder” or “previously unreported and probably not 
causative of disease”.46 The CMGS 2007 guidelines also 
state that it is “essential to report all UVs where the 
clinical significance is uncertain” and furthermore that 
it is “essential that reports of UVs should be issued 
to appropriately trained clinicians”.44 The European 
Molecular Genetics Quality Network’s best practice 
guidelines for genetic analysis in hereditary breast 
ovarian cancer recommend that the identification of 
BRCA gene VUS do not “provide a basis for changing 
the clinical management of the patient or for offering 
predictive testing to at risk relatives”.6
The protocol which the authors have established 
for interpreting BRCA gene missense variants 
includes: (1) Checking the Breast Cancer Information 
Core (BIC)and IARC databases;8,16 (2) Checking the 
dbSNP for classification and minor allele frequency;19 
(3) Undertaking splice site predictions using the online 
Splice Site Prediction by Neural Network and ASSP 
tools,11,13 and (4) Undertaking in silico protein analysis 
using the Grantham score PolyPhen SIFT BLink, 
SNPs&GO and PROVEAN.2,20,28,32,40
In the event that a database search is conflicting, or 
there is no entry, the authors recommend that dbSNP 
and splice site/in silico protein analysis programmes 
are also used. Apart from the BIC and IARC databases, 
other databases are not as comprehensive, or provide 
little value in assigning benign/disease-causing status 
to a missense variant.
The in silico programmes use a variety of 
approaches to achieve a prediction: sequence and 
Table 4: Percentage of BRCA1 and BRCA2 gene 
missense variants predicted to be pathogenic using 
online in silico analysis programmes




PolyPhen - HumDiv 50
SIFT 46









SNP&GO = predicts human disease-related mutations in 
proteins with functional annotations;28,29 SNAP = predicts effect 
of non-synonymous polymorphisms on function;34,35 PolyPhen = 
Polymorphism Phenotyping, Version 2;20,21 SIFT = Sorting Intolerant 
from Tolerant BLink;40,41 MutPred = Version 1.2, classifies an amino 
acid substitution as disease-associated or neutral;26,27 PhD-SNP = 
Predictor of Human Deleterious Single Nucleotide Polymorphisms;36 
PROVEAN = Protein Variation Effect Analyzer, Version 1.1.3;37–39 
PANTHER = Protein Analysis Through Evolutionary Relationships, 
Version 6.1;30,31 MutAss = Mutation Assessor programme, release 2;22,23 
I-Mutant = Version 3.0;24,25 Align-GVGD = Align-Grantham Variation 
Grantham Deviation;32,33 MutTast = Mutation Taster.42,43
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evolutionary conservation-based methods, protein 
sequence and structure-based methods and machine 
learning methods. The data from this study support 
using a number of programmes to achieve a consensus 
prediction rather than relying on only one programme. 
The authors suggest that, when results are uncertain, 
a report of the cascade approach used should be 
recorded and a detailed work-up should be archived 
for the clinician to refer to if necessary. 
The authors recommend that their conclusions 
are reviewed by clinicians to determine their 
continuing validity. The predictions have varying 
levels of confidence, but are considered as an aid to 
clinical interpretation, although the work described 
here shows that the value of these predictions may be 
largely ambivalent at best, or misleading at worst. The 
authors recommend that the testing of additional family 
members and a correlation with clinical findings would 
be helpful to determine the significance of the result. 
This recommendation for segregation analysis 
is not entirely fool-proof, especially in light of the 
predominance of breast cancer in families with 
BRCA1/2 gene mutations, and that cancer risk may 
involve an appreciation of familial context rather 
than a population-based calculation.47 Critically, the 
authors suggest only accepting referrals from trained 
genetic counsellors or clinicians with a sufficient 
understanding of interpreting complicated genetic 
results. In the event of BRCA gene missense mutations 
that are reliably benign (stated as such in BIC/IARC 
databases or when all in silico predictions agree), then 
these should be relegated to an ancillary table in the 
report with a footnote indicating how the benign 
status was determined.
This study highlights the complexity of interpreting 
and reporting missense BRCA1/2 gene variants 
where the results will be used in genetic counselling, 
screening and disease prevention. It demonstrates that 
some BRCA gene missense variants cannot be clearly 
interpreted with the tools and data available today; 
however, these variants must be included in laboratory 
reports so that if future information becomes available 
regarding their classification then this can be passed on 
to the patient and their family. This future information 
could be provided by international developments 
under the auspices of the Enhancing Neuro Imaging 
Genetics through Meta Analysis Consortium which 
is involved in coordinating the development of 
algorithms for the classification of variants in the 
BRCA1/2 genes.48 Recent work reported by this 
consortium has embraced functional assays of BRCA2 
gene variants and has attempted to translate functional 
outcomes into a probability of pathogenicity.49
Conclusion
The findings of this study show that there is significant 
discordance in the classification of some missense 
variants in the BRCA genes when using online mutation 
databases and carrying out in silico analyses. This 
discordance leads to complexities in interpreting and 
reporting these variants in a clinical context. As such, 
it is vital that laboratories have agreed guidelines for 
determining the pathogenicity of a given variant based 
on a wide range of information and for reporting an 
uncertain result to the referring clinician. Importantly, 
the complexity of interpreting and communicating 
VUS findings highlights the importance of sequencing 
results being conveyed to patients in a specialist 
genetic counselling environment.
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